Researchers at the University of Delaware have developed a model that combines artificial intelligence with magnetic resonance elastography (MRE) to…
Andrea Lobo
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo
Newronika is preparing for the commercial launch of AlphaDBS — a next-generation adaptive deep brain stimulation (DBS) system…
Neuropacs‘ MRI-based artificial intelligence (AI) technology demonstrated 96% accuracy in distinguishing Parkinson’s disease from atypical parkinsonism — including…
Parkinson Italia — a network of 30 associations for patients and caregivers in Italy — is backing an initiative…
Most people with early-stage Parkinson’s disease have sleep disturbances, with many having more than one at the same time,…
Angels on Call, a home care services provider, has been recognized as a Community Partner in Parkinson’s Care…
A researcher at the University of Wollongong in Australia has received funding of nearly 400,000 Australian dollars (about $250,000) to…
Among people with rapid eye movement (REM) sleep behavior disorder, blood biomarkers associated with dementia may help identify those at…
A Phase 2a clinical trial testing Ventus Therapeutics’ VENT-02 — a novel brain-penetrating oral medication — in adults with mild…
Note: This story was updated March 13, 2025, to correct that the company’s proprietary software is not available as a…